<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canada Vigilance &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/canada-vigilance/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 10 Oct 2026 23:58:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Canada Vigilance &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Liver Injury After CAR T-Cell Therapy May Be Driven by Cytokine Storm, Landmark Analysis Finds</title>
		<link>https://bioengineer.org/liver-injury-after-car-t-cell-therapy-may-be-driven-by-cytokine-storm-landmark-analysis-finds/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 10 Oct 2026 23:58:32 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Canada Vigilance]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[cytokine release syndrome]]></category>
		<category><![CDATA[drug-induced liver injury]]></category>
		<category><![CDATA[FAERS]]></category>
		<category><![CDATA[haemophagocytic lymphohistiocytosis]]></category>
		<category><![CDATA[Hematology]]></category>
		<category><![CDATA[hepatic adverse events]]></category>
		<category><![CDATA[idecabtagene vicleucel]]></category>
		<category><![CDATA[immunotherapy toxicity]]></category>
		<category><![CDATA[liver injury]]></category>
		<category><![CDATA[Pharmacovigilance]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=413553</guid>

					<description><![CDATA[A pharmacovigilance analysis of nearly five million adverse-event reports finds that liver injury after CAR T-cell therapy is predominantly early and linked to cytokine release syndrome, though a persistent CRS-independent signal with idecabtagene vicleucel warrants prospective study.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">413553</post-id>	</item>
	</channel>
</rss>
